Recent advances in the treatment of polycystic ovary syndrome

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Expert Opinion on Investigational Drugs

• Publication date

  2004-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/13543784.13.10.1295PMID 15461558
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Progestogens with Antiandrogenic Properties

  2012cited by this paper
• Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).

  2004cited by this paper
• Effect of pioglitazone treatment on the adrenal androgen response to corticotrophin in obese patients with polycystic ovary syndrome.

  2004cited by this paper
• Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study.

  2004cited by this paper
• Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome.

  2004cited by this paper
• Medical treatment regimens of hirsutism.

  2004cited by this paper
• Assessment of glucose intolerance and insulin sensitivity in polycystic ovary syndrome.

  2004cited by this paper
• Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome.

  2004cited by this paper
• Insulin sensitization early after menarche prevents progression from precocious pubarche to polycystic ovary syndrome.

  2004cited by this paper
• Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome.

  2004cited by this paper
• Drospirenone, a progestogen with antimineralocorticoid properties: a short review.

  2004cited by this paper
• Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study.

  2004cited by this paper
• Enhanced granulosa cell responsiveness to follicle-stimulating hormone during insulin infusion in women with polycystic ovary syndrome treated with pioglitazone.

  2003cited by this paper
• Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome.

  2003cited by this paper
• Polycystic ovary syndrome and endometrial carcinoma.

  2003cited by this paper
• Correction of Insulin Resistance and Hyperandrogenism in Polycystic Ovary Syndrome By Combined Rosiglitazone and Clomiphene Citrate Therapy

  2003cited by this paper
• Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome.

  2003cited by this paper
• Polycystic ovary syndrome and cardiovascular disease: a premature association?

  2003cited by this paper
• Minimal response of circulating lipids in women with polycystic ovary syndrome to improvement in insulin sensitivity with troglitazone.

  2003cited by this paper
• Erratum: Polycystic ovary syndrome and endometrial carcinoma (Lancet (May 24, 2003) 361 (1810-1812))

  2003cited by this paper
• Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin.

  2003cited by this paper
• Thiazolidinediones – some recent developments

  2003cited by this paper
• Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome.

  2003cited by this paper
• Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome.

  2003influential reference
• Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome.

  2003cited by this paper
• Relation of intra-abdominal fat distribution to metabolic disorders in nonobese patients with polycystic ovary syndrome.

  2003cited by this paper
• Metformin: An Update

  2002cited by this paper
• Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus.

  2002cited by this paper
• Global fibrinolytic capacity is decreased in polycystic ovary syndrome, suggesting a prothrombotic state.

  2002cited by this paper
• Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives.

  2002cited by this paper
• Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome.

  2002cited by this paper
• Anti-androgens for the treatment of hirsutism

  2002cited by this paper
• The mechanisms of action of PPARs.

  2002cited by this paper
• Differentiating members of the thiazolidinedione class: a focus on safety

  2002cited by this paper
• Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome.

  2002cited by this paper
• Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.

  2002cited by this paper
• Co-administration of metformin during rFSH treatment in patients with clomiphene citrate-resistant polycystic ovarian syndrome: a prospective randomized trial.

  2002cited by this paper
• Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial.

  2001cited by this paper
• Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome.

  2001cited by this paper
• Efficacy of the combination ethinyl oestradiol and cyproterone acetate on endocrine, clinical and ultrasonographic profile in polycystic ovarian syndrome.

  2001cited by this paper
• Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.

  2001cited by this paper
• Prevalence of type 2 diabetes mellitus and impaired glucose tolerance in Asian women with polycystic ovary syndrome

  2001cited by this paper
• The impact of ethnicity on the presentation of polycystic ovarian syndrome

  2001cited by this paper
• Thiazolidinediones and liver toxicity.

  2001cited by this paper
• D‐Chiro‐Inositol in Insulin Action and Insulin Resistance ‐ Old‐Fashioned Biochemistry Still at Work

  2001cited by this paper
• Improvement in insulin sensitivity followed by ovulation and pregnancy in a woman with polycystic ovary syndrome who was treated with rosiglitazone.

  2001cited by this paper
• Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome.

  2001cited by this paper
• Polycystic ovary syndrome and ovulation induction.

  2001cited by this paper
• Polycystic ovary syndrome, infertility, familial thrombophilia, familial hypofibrinolysis, recurrent loss of in vitro fertilized embryos, and miscarriage.

  2000cited by this paper
• Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial.

  2000cited by this paper
• Hyperinsulinemia in polycystic ovary syndrome correlates with increased cardiovascular risk independent of obesity.

  2000cited by this paper
• Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone.

  1999cited by this paper
• The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2000 by The Endocrine Society A Prospective Study of the Prevalence of the Polycystic Ovary Syndrome in Unselected Caucasian Women from Spain*

  1999cited by this paper
• Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome.

  1999cited by this paper
• Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome

  1999cited by this paper
• A prospective randomized trial comparing low dose flutamide, finasteride, ketoconazole, and cyproterone acetate-estrogen regimens in the treatment of hirsutism.

  1999cited by this paper
• Current aspects of antiandrogen therapy in women.

  1999cited by this paper
• A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile.

  1999cited by this paper
• Low-dose FSH therapy for anovulatory infertility associated with polycystic ovary syndrome: rationale, results, reflections and refinements.

  1999cited by this paper
• Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.

  1999cited by this paper
• Update on oral contraceptive pills.

  1999cited by this paper
• Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women.

  1999cited by this paper
• Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment.

  1998cited by this paper
• A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome.

  1998cited by this paper
• Idiopathic hirsutism: an uncommon cause of hirsutism in Alabama.

  1998cited by this paper
• Hyperandrogenic anovulation (the polycystic ovary syndrome)--back to the ovary?

  1998cited by this paper
• Troglitazone Improves Defects in Insulin Action , Insulin Secretion , Ovarian Steroidogenesis , and Fibrinolysis in Women with Polycystic Ovary Syndrome *

  1997cited by this paper
• Gonadotrophin-releasing hormone agonist therapy for hirsutism is as effective as high dose cyproterone acetate but results in a longer remission.

  1997cited by this paper
• Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis.

  1997cited by this paper
• Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome.

  1997cited by this paper
• Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome.

  1996cited by this paper
• The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome.

  1996cited by this paper
• Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women.

  1995influential reference
• Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome.

  1995cited by this paper
• Leuprolide and estrogen versus oral contraceptive pills for the treatment of hirsutism: a prospective randomized study.

  1995cited by this paper
• The role of oral contraceptives in the treatment of hyperandrogenic disorders.

  1995cited by this paper
• Insulin action in human granulosa cells from normal and polycystic ovaries is mediated by the insulin receptor and not the type-I insulin-like growth factor receptor.

  1995cited by this paper
• Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.

  1994cited by this paper
• Endocrine consequences of weight loss in obese, hyperandrogenic, anovulatory women.

  1994cited by this paper
• Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial.

  1994cited by this paper
• Comparison of the efficacy of spironolactone versus flutamide in the treatment of hirsutism.

  1994cited by this paper
• Body fat distribution has weight-independent effects on clinical, hormonal, and metabolic features of women with polycystic ovary syndrome.

  1994cited by this paper
• Therapeutic Use of Gonadotropin‐Releasing Hormone Agonists in Polycystic Ovarian Syndrome

  1993influential reference
• Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome?

  1992cited by this paper
• Cellular mechanisms of insulin resistance in polycystic ovarian syndrome.

  1992cited by this paper
• Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome

  1992cited by this paper
• Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome

  1992cited by this paper
• Evidence for Distinctive and Intrinsic Defects in Insulin Action in Polycystic Ovary Syndrome

  1992cited by this paper
• Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome.

  1992cited by this paper
• A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome.

  1991influential reference
• Profound Peripheral Insulin Resistance, Independent of Obesity, in Polycystic Ovary Syndrome

  1989cited by this paper
• [Diagnostic criteria for polycystic ovary syndrome].

  1989cited by this paper
• Spironolactone is an effective and well tolerated systemic antiandrogen therapy for Hirsute women.

  1989influential reference
• Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss.

  1989cited by this paper
• Side-effects of spironolactone therapy in the hirsute woman.

  1988cited by this paper
• Clinical efficacy and safety of cyproterone acetate in severe hirsutism: results of a multicentered Canadian study.

  1986cited by this paper
• Anti‐androgen treatment in women with acne: a controlled trial

  1986cited by this paper
• The effects of spironolactone on adrenal steroidogenesis in hirsute women.

  1985cited by this paper
• Sensitivity of cortisol and adrenal androgens to dexamethasone suppression in hirsute women.

  1985cited by this paper
• Androgen metabolism in hirsute patients treated with cyproterone acetate.

  1984cited by this paper

• Butyric acid ameliorates PCOS-related reproductive dysfunction through gut-brain-ovary axis signaling and ovarian steroidogenic factor activation

  2025cites this paper
• Alternative treatment of polycystic ovary syndrome: pre-clinical and clinical basis for using plant-based drugs

  2024cites this paper
• Polycystic ovary syndrome and metabolic syndrome: possible ways to correct metabolic disorders

  2024cites this paper
• A policy brief on improving the lifestyle of women with polycystic ovary syndrome

  2024cites this paper
• Effects of myo-inositol vs. metformin on hormonal and metabolic parameters in women with PCOS: a meta-analysis

  2023cites this paper
• A review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome

  2020cites this paper
• The insulin sensitizer mechanism of Myo-inositol is associated to AMPK activation and GLUT-4 expression in human endometrial cells exposed to a PCOS environment.

  2019cites this paper
• Gestagen versus oral contraceptive pills to induce withdrawal bleeding before induction of ovulation by clomiphene citrate in polycystic ovary syndrome

  2014cites this paper
• Oral contraceptives in polycystic ovary syndrome.

  2014cites this paper
• The metabolic effects of drugs used for the treatment of polycystic ovary syndrome.

  2013cites this paper
• Clinical efficacy and metabolic impact of two different dosages of ethinyl-estradiol in association with drospirenone in normal-weight women with polycystic ovary syndrome: A randomized study

  2013cites this paper
• Combined Pioglitazone and Clomiphene Citrate Versus Metformin and Clomiphene Citrate in Clomiphene Citrate Resistant Women with PCOS

  2013cites this paper
• Assessment, diagnosis and treatment of a patient with hirsutism

  2008cites this paper
• Oral Contraceptives in Polycystic Ovary Syndrome: Risk-Benefit Assessment

  2008influential citation
• Polycystic Ovary Syndrome: Insulin sensitizers in the treatment of polycystic ovary syndrome

  2007cites this paper
• Polikistik over sendromu

  2005cites this paper
• Preoperative luteinizing hormone levels predict the ovulatory response to laparoscopic ovarian drilling in patients with clomiphene citrate-resistant polycystic ovary syndrome

  2005cites this paper
• Insulin-sensitisers in the treatment of polycystic ovary syndrome

  2005cites this paper